Arrow-right Camera

The Spokesman-Review Newspaper The Spokesman-Review

Wednesday, August 21, 2019  Spokane, Washington  Est. May 19, 1883
Clear Night 61° Clear
News >  Nation

FDA OKs 1st generic nasal spray of overdose reversal drug

This Sept. 7, 2017 photo shows a box of Narcan spray displayed after a news conference in Cincinnati. U.S. regulators have approved the first generic nasal spray version of Narcan, a drug that reverses opioid overdoses. (John Minchillo / AP)
This Sept. 7, 2017 photo shows a box of Narcan spray displayed after a news conference in Cincinnati. U.S. regulators have approved the first generic nasal spray version of Narcan, a drug that reverses opioid overdoses. (John Minchillo / AP)
By Linda A. Johnson Associated Press

U.S. regulators have approved the first generic nasal spray version of Narcan, a drug that reverses opioid overdoses.

The Food and Drug Administration on Friday OK’d naloxone spray from Israel’s Teva Pharmaceuticals.

Naloxone has been sold as a nasal spray in the U.S. since 2016 under the brand name Narcan. Pharmacists can dispense it without a prescription. It is also sold as a generic or brand-name drug in automatic injectors, prefilled syringes and vials.

A pack of two Narcan nasal sprays cost about $130 to $150 without insurance. Teva didn’t immediately provide the product’s price or when it will be available; its offices were closed Friday.

More than 47,600 Americans died of opioid overdoses in 2017, a toll that has been rising for two decades.

Subscribe to the Morning Review newsletter

Get the day’s top headlines delivered to your inbox every morning by subscribing to our newsletter.

You have been successfully subscribed!
There was a problem subscribing you to the newsletter. Double check your email and try again, or email webteam@spokesman.com